SCHEDULE: TomEnterprise Group Discloses 16.28% Stake in DiaMedica Therapeutics
Beneficial Ownership Amendment
TomEnterprise AB, TomEnterprise Private AB, and Thomas von Koch have collectively reported beneficial ownership of 16.28% of DiaMedica Therapeutics Inc.'s common shares.
Summary
- TomEnterprise AB, TomEnterprise Private AB, and Thomas von Koch (collectively, the "Reporting Persons") have filed an Amendment No. 4 to Schedule 13G.
- The Reporting Persons beneficially own an aggregate of 8,383,577 common shares of DiaMedica Therapeutics Inc.
- This ownership represents 16.28% of the issuer's common shares.
- The percentage is calculated based on 42,883,465 shares outstanding as of May 9, 2025, plus 8,606,426 shares contemplated to be issued in a private placement, totaling 51,489,891 shares.
- Thomas von Koch, as the sole owner of TomEnterprise AB, which wholly owns TomEQT AB, which wholly owns TomEnterprise Private AB, is deemed to have sole voting and dispositive power over all the beneficially owned shares.
- The filing certifies that the securities were not acquired and are not held for the purpose or effect of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's performance or prospects. It is a routine regulatory update.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of beneficial ownership, indicating a significant stake held by a group of investors in a biotechnology or pharmaceutical company. Such disclosures are common and provide transparency regarding major shareholders, which can be relevant for corporate governance and market perception.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant beneficial owner and the concentration of ownership.
- Regulatory Authorities: Fulfills SEC disclosure requirements for significant ownership stakes.
Key Dates
| Date | Description |
|---|---|
| 2025-03-31 | End of quarter for which DiaMedica Therapeutics Inc.'s Form 10-Q reported outstanding shares. |
| 2025-05-09 | Date as of which 42,883,465 shares of DiaMedica Therapeutics Inc.'s Common Stock were reported outstanding. |
| 2025-05-13 | Date DiaMedica Therapeutics Inc. filed its quarterly report on Form 10-Q for the quarter ended March 31, 2025. |
| 2025-07-21 | Date DiaMedica Therapeutics Inc. filed a Current Report on Form 8-K describing a private placement. |
| 2025-07-23 | Date of event which requires filing of this Schedule 13G statement. |
| 2025-07-30 | Signature date of the Schedule 13G filing by the Reporting Persons. |
Keywords
DiaMedica Therapeutics, Beneficial Ownership, Schedule 13G, SEC Filing, Common Shares, TomEnterprise AB, Thomas von Koch, Equity Stake, Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.